Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus SELFEMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus SELFEMRA.
ASHLYNA vs SELFEMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptor alpha (ERα), inducing its degradation and inhibiting estrogen-dependent cell proliferation.
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
1 tablet (50 mg) orally once daily with food.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life of 12-16 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Primarily renal excretion as unchanged drug (50-60%) and metabolites (20-30%); biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal